Biotage, a life science company that provides separation and synthesis technologies, agreed to merge with KKR-backed Gamma Biosciences, a global life sciences platform, in a $235m deal. "This move brings together two highly regarded and complementary businesses creating a differentiated player in the field of chromatography. Astrea is quickly becoming one of the leaders in its field with an incredible pipeline of innovation targeting advanced therapeutics. We are excited to join forces with the team at Biotage and leverage the strong foundation that they've established to rapidly grow these businesses together," Matt Gunnison, Gamma Biosciences CEO.